Jack Kavanaugh Email & Phone Number

Sunny Isles Beach, Florida, Us

Nanotech Energy is on a mission to bring transformative, graphene-based, energy storage products from the research lab to the mass market, revolutionizing the way we power our world. Our very high surface area, single layer graphene material is already being used in multiple applications, including non-flammable batteries, transparent conducting electrodes, conductive inks, printed electronics, conductive epoxy, antistatic coatings and EMI (electromagnetic interference) shielding.It is the only current producer of highest performance non-flammable batteries and 95% monolayer graphene.

Galway, Ie

Orbsen is a clinical stage stromal cell immunotherapy company that is redefining cell therapy using proprietary GMP-compliant and scalable positive-selection purification strategies to develop ground-breaking, second generation stromal cell treatments to address some of today’s most challenging diseases. It has received approximately $55 million in non-legacy funding grants for different targeted clinical trials.

SuperMetalix has created the hardest metal ever made and the only metal hard enough to scratch a diamond. It produces cost-efficient super-hard metallic composites which are twice as hard as carbide and less than half the weight that are far superior to today’s commonly-used hard metals.

Novonco targets multiple hard-to-treat cancers. Its three platform technologies are the result of years of investigation into the medicinal chemistry and cancer biology of various tumors. These molecularly-targeted drugs represent the next generation of cancer therapies, offering hope to patients with limited treatment options, including those with acute myelogenous leukemia, ovarian, pancreatic, prostate, brain, liver, and other cancers.

Silq, Inc. created a unique material that treats composites and does not allow bacterial or fungal growth and therefore prevents infections from multiple types of medical devices. FDA approval has already been received for urinary catheters. Dozens of additional medical devices are expected to follow. It has also been determined that the technology does not allow fibrinogen attachment, therefore it also prevents blood clot formation. The technology additionally applies to industrial applications by preventing bacterial growth on water filters, tubing and vats for the beverage industry, desalination plant tubes, and others. Its high state of lubricity (lack of friction) for composites such as silicone makes it ideal for multiple additional industrial and medical applications.

Senior Manager of Multiverse Fund I (fully invested and taking no further investors) and Multiverse Fund II (which has just launched). Both funds are diversified investments into companies that have unique product offerings, most of which have gatekeeper type technology which could have significant beneficial impact on society and produce significant returns to investors.

Fortem has developed a therapeutic that has shown great promise in animal studies in significantly improving the cognitive capabilities of dementia and Alzheimer’s. It is targeting human trials next.

VaultPharma is creating vaccines for Chlamydia, oral and cervical cancer and a therapeutic against a number of cancers, including pulmonary and brain cancers. It is targeting human trials next.

Los Angeles, California, Us

Westwood Bioscience utilizes the silicasome as a therapeutic delivery device against a variety of cancers, and has demonstrated significant efficacy and safety improvement over the current liposome technology, an $8 billion revenue product.

LongLifeRx, Inc. has two neurtraceutical products available online; Coggevity targets improved cognitive performance and MyLife Therapeutics targets longevity, kidney and heart function. The analogues are targeted to improve kidney, brain and heart function, as well as slowing the aging process and will require human trials.

Black Light Surgical received a “Breakthrough Therapeutic” designation from the FDA for its technology. Black Light has developed a technology that in the surgical suite can quickly determine cancer from non-cancerous tissue with 99% specificity and 99% sensitivity. It has thus far been applied to breast, brain, and lung cancers. It is planning on expanding to be applied to dermatologic, cervical, oral, eye, and gastric cancers, as well as colonoscopy screening.

As Dr. Kavanaugh predicted, Dr. Grubbs received the Nobel Prize for chemistry in November,2005 for the technology held by this Cal-Tech spin-out chemical company. Materia holds morethan 300 patents and multiple product applications.

Acquired: Celgene 2018 enterprise value of $10.1 billionKavanaugh successfully combined exclusive technological licensing from top healthcare andresearch institutions to place ZetaRx at the leading edge of immunotherapy (CAR-Tcell) for thetreatment of cancer. The ZetaRx IP portfolio and clinical trial strategy continued as the core of Juno Therapeutics, Inc quickly having its IPO and reaching a market cap of approximately $5.5Billion. A few years later it was purchased by Celgene for an enterprise value of $10.1 Billion.He is especially proud of the human clinical trial he enabled that reported the best results in the history of cancer therapeutics for terminal patients.

Calhoun is a biotechnology firm that developed the world’s first and only light adjustableintraocular lens for cataract surgery. Dr. Kavanaugh played a very important and pivotal role inassisting Calhoun from its inception at CalTech to commercialization abroad (approved inEurope with a CE Mark and also in Mexico) and in leading the company into and through thestages of US clinical trials. Its industry leading and disruptive product received final FDAapproval and is scaling commercial sales.

Houston, Tx, Us

Acquired by Wex 2018 Dr. Kavanaugh was a Board member of PreCash. His efforts in 2001 staved off an imminent insolvency proceeding, and helped to lead a major turn-around. Two years later PreCash was rated by Inc. Magazine as one of the fastest growing companies in profits in the United States.

Dr. Kavanaugh was the founder and served as Chairman and CEO of Amerident, a health care service provider which he founded in 1996, grew organically from 1 to approximately 500 employees and sold at a significant multiple of invested capital to a public company approximately two and a half years from inception, in 1999. Amerident received over 30 community service awards and a state congressional medal of honor for its work with infants.

Dr. Kavanaugh was responsible for taking public Team Global (1986), where, as a member of the Board for several years, he helped guide and create value as the public share price rose approximately 300 X from an initial investor cost of 11 cents per share to approximately $33 per share.

Among multiple strategic consulting projects and Mergers & Acquisitions Dr. Kavanaugh led were Merck’s Mexican merger, a global mining strategy, the merger that created Cemex, and a global tuna fishing industry study and strategy development.

Specialty Degree In Ophthalmology (Residency)

Doctor Of Medicine (M.D.)

Medicine

Master Of Business Administration (Mba)

D.D.S.

Bachelor Of Arts (B.A.)